SCHEMBL3219267

SCHEMBL3219267

N=C(N)c1cccc[n+]1[O-]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
F2 P00734 2/20 0.39
F10 P00742 1/20 0.39
F12 P00748 1/20 0.39
F7 P08709 1/20 0.39
F3 P13726 1/20 0.39
PKM P14618 1/20 0.39
BLM P54132 1/20 0.38
PRSS1 P07477 3/20 0.37
PRSS2 P07478 2/20 0.37
PRSS3 P35030 2/20 0.37
KMT2A Q03164 2/20 0.37
C1S P09871 1/20 0.37
RECQL P46063 1/20 0.37
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
WDR5 P61964 1/20 0.34
PLG P00747 1/20 0.32
PLAU P00749 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17984647 0.98 BLM (0.41) LMNAHTTF2F10F12
SCHEMBL2833136 0.78 KDM4E (0.43) LMNAHTTBLMKMT2ARECQL
SCHEMBL30488814 0.78 KDM4E (0.43) LMNAHTTBLMKMT2ARECQL
SCHEMBL1446754 0.75 LMNA (0.38) LMNAHTTKDM4ETDP1SLC2A1
SCHEMBL31678925 0.75 LMNA (0.38) LMNAHTTKDM4ETDP1SLC2A1
SCHEMBL1446751 0.75 LMNA (0.38) LMNAHTTKDM4ETDP1SLC2A1
SCHEMBL1446755 0.75 LMNA (0.38) LMNAHTTKMT2AKDM4ETDP1
SCHEMBL5633991 0.74 HDAC8 (0.41) F2F10F12F7F3
SCHEMBL1489277 0.71 KDM4E (0.44) LMNAHTTKMT2AKDM4ETDP1
SCHEMBL30040657 0.71 LMNA (0.41) LMNAHTTKMT2AKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 LMNA 3470/4885HTT 2449/4885F2 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.